Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel, also work in different ways to kill tumor cells or stop them from growing. Giving bevacizumab together with docetaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with docetaxel works in treating older patients with stage III or stage IV non-small cell lung cancer.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Mar 27, 2019 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Interventions being studied
- Biological: bevacizumab; Drug: docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed non-small cell lung cancer
- Stage III or IV disease
- Stage III disease allowed, provided the patient is not a candidate for concurrent chemotherapy and radiotherapy
- Mixed histology allowed, provided the biopsy has less than 50% squamous cell histology
- Measurable or evaluable disease
- Squamous cell histology
- Evidence of cavitation in the tumor
- Tumors in close proximity to major blood vessels
- No active, untreated brain metastases
- More than 7 days since prior treatment for brain metastases AND no evidence of hemorrhage in the lesion
- Stable or declining dose of steroids allowed PATIENT CHARACTERISTICS: Inclusion criteria:
- ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
- Life expectancy \> 12 weeks
- Leukocytes ≥ 3,000/μL
- Absolute neutrophil count ≥ 1,500/μL
- Platelet count ≥ 100,000/μL
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST and ALT ≤ 2.5 times ULN (\< 5 times ULN if patients has liver metastases)
- Creatinine ≤ 1.5 times normal
- Left ventricular function ≥ normal by MUGA scan or ECHO
- Urine protein:creatinine ratio ≤ 1.0 AND/OR urine protein ≤ 1+ by dipstick analysis OR protein ≤ 1 g/24-hour urine collection
- Fertile patients must use effective contraception and women should avoid breastfeeding
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Barbara Ann Karmanos Cancer InstituteDetroit, Michigan
- Nevada Cancer InstituteLas Vegas, Nevada
- Case Comprehensive Cancer CenterCleveland, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 27, 2019. Always confirm current availability with the study team.